Amodiaquin
 Amodiaquin | |
|---|---|
type of chemical entity (en)  | |
| Bayanai | |
| Ƙaramin ɓangare na | antimalarial (en) |
| Amfani | magani |
| Sinadaran dabara | C₂₀H₂₂ClN₃O |
| Canonical SMILES (en) | CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O |
| LiverTox likelihood score (en) | LiverTox toxicity likelihood category A (en) |
| Subject has role (en) | antimalarial (en) , WHO essential medicines (en) da bactericide (en) |
Amodiaquin (ADQ) magani ne da ake amfani da shi don magance zazzabin cizon sauro, gami da Plasmodium falciparum zazzabin sauro lokacin da ba shi da matsala.[1][2] An ba da shawarar a ba da shi tare da Artisunate don rage haɗarin juriya.[1] Saboda haɗarin haɗari amma mummunan sakamako, ba a ba da shawarar hana zazzabin cizon sauro gaba ɗaya ba.[1] Ko da yake, Hukumar Lafiya ta Duniya (WHO) a cikin 2013 ta ba da shawarar amfani da rigakafin yanayi a cikin yara da ke cikin haɗari mai girma a hade tare da sulfadoxine da pyrimethamine.
Amodiaquine wani fili ne na 4-aminoquinoline wanda ke da alaƙa da chloroquine . [1] Sakamakon amodiaquine gabaɗaya ƙananan ne zuwa matsakaici kuma suna kama da na chloroquine.[2] Matsalolin hanta da ba su da yawa ko ƙananan ƙwayoyin jini na iya faruwa.[1] Lokacin da aka ɗauka da ciwon kai, matsala ta gani, fashewa, da kuma dakatar da zuciya na iya faruwa.[1] WHO ta ba da shawarar amfani da shi ga mata masu juna biyu a lokacin watanni uku na biyu da na uku da kuma lokacin shayarwa, amma ta ba da rahoton cewa shaidar amfani a cikin watanni uku na farko har yanzu bai isa ba.[3]
An fara yin Amodiaquine a shekarar 1948. Yana cikin Jerin Magunguna Masu Muhimmanci na Hukumar Lafiya ta Duniya. Duk da yake ba a samuwa a Amurka ba, yana samuwa a ko'ina a Afirka. [4][1][5]
Amfani da kiwon lafiya
[gyara sashe | gyara masomin]Amodiaquine ya zama muhimmiyar magani a cikin maganin haɗuwa don maganin zazzabin cizon sauro a Afirka.[6] Sau da yawa ana amfani dashi a hade tare da Artisunate a matsayin maganin haɗin gwiwar artemisinin (ACT) don cutar zazzabin cizon sauro mara rikitarwa. An kuma gano Amodiaquine don aiki akan nau'ikan cutar zazzabin cizon sauro masu tsayayya da chloroquine, kodayake akwai bambancin ƙasa a cikin aikinsa akan nau'in da ke tsayayya le chloroquin.[7]
Hakanan ana amfani dashi tare da sulfadoxine / pyrimethamine . [8]
Ma'amala
[gyara sashe | gyara masomin]An samu rahotanni game da karuwar guba a cikin hanta a cikin mutanen da ke da cutar kanjamau / AIDS a kan zidovudine ko efavirenz lokacin da aka kula da tsarin ACT mai dauke da amodiaquine, saboda haka ana ba da shawarar cewa waɗannan mutane su guji amodiaquin.
Pharmacokinetics da pharmacogenetics
[gyara sashe | gyara masomin]Ana kunna shi ta hanyar hanta zuwa ainihin metabolite, N-desethylamodiaquine, ta hanyar enzyme Cytochrome p450 CYP2C8. Daga cikin masu amfani da amodiaquine, an bayar da rahoton sakamako masu yawa amma masu tsanani kuma suna da alaƙa da bambance-bambance a cikin CYP2C8 alleles. CYP2C8 * 1 an bayyana shi azaman nau'Irin daji, wanda ke nuna bayanin aminci mai karɓa, yayin da CYP2C 8 * 2, * 3 da * 4 duk suna nuna kewayon "matalauta" phenotypes. Mutanen da ba su da ƙwayoyin cuta na amodiaquine suna nuna ƙarancin ingancin magani akan zazzabin cizon sauro, da kuma karuwar guba.[1] An gudanar da bincike da yawa don tantance yaduwar ƙwayoyin CYP2C8 tsakanin marasa lafiya na zazzabin cizon sauro a Gabashin Afirka, kuma sun nuna cewa bambancin ƙwayoyin suna da yaduwa a cikin wannan yawan.[2] Kimanin kashi 3.6% na yawan mutanen da aka yi nazari sun nuna babban haɗari don mummunar amsawa ko rage sakamakon magani lokacin da aka yi musu magani da amodiaquine. Wannan bayanin yana da amfani wajen bunkasa shirye-shiryen tsaro na magunguna a Gabashin Afirka, kuma suna da mahimman la'akari na asibiti don ba da magungunan rigakafin zazzabin cizon sauro a yankuna masu yawan bambancin CYP2C8.
Dubi kuma
[gyara sashe | gyara masomin]- Irin wannan tsari shine FGI-104
Manazarta
[gyara sashe | gyara masomin]- 1 2 3 4 5 6 7 Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, Shah VP, Dressman JB (December 2012). "Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride". Journal of Pharmaceutical Sciences. 101 (12): 4390–4401. Bibcode:2012JPhmS.101.4390N. doi:10.1002/jps.23312. PMID 22949374. Cite error: Invalid
<ref>tag; name "Na2012" defined multiple times with different content. - 1 2 Olliaro P, Mussano P (2003). "Amodiaquine for treating malaria". The Cochrane Database of Systematic Reviews. 2019 (2). doi:10.1002/14651858.CD000016. PMC 6532704. PMID 12804382. Cite error: Invalid
<ref>tag; name "Co2003" defined multiple times with different content. - ↑ "WHO Guidelines for malaria". www.who.int (in Turanci). Retrieved 2024-01-22.
- ↑ "Amodiaquine". 2012. PMID 31643176. Archived from the original on 27 November 2016. Retrieved 27 November 2016. Cite journal requires
|journal=(help) - ↑ Centers for Disease Control (CDC) (April 1985). "Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum". MMWR. Morbidity and Mortality Weekly Report. 34 (14): 185–90, 195. PMID 3156271.
- ↑ Kerb R, Fux R, Mörike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M (December 2009). "Pharmacogenetics of antimalarial drugs: effect on metabolism and transport". The Lancet. Infectious Diseases. 9 (12): 760–774. doi:10.1016/S1473-3099(09)70320-2. PMID 19926036.
- ↑ "Amodiaquine". PubChem. U.S. National Library of Medicine. Archived from the original on 2016-10-29. Retrieved 2016-10-28.
- ↑ Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ (August 2001). "Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial". Lancet. 358 (9279): 368–374. doi:10.1016/S0140-6736(01)05557-X. PMID 11502317. S2CID 42745422.
